(NASDAQ: AVXL) Anavex Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.81%.
Anavex Life Sciences's earnings in 2026 is -$13,022,000.On average, 3 Wall Street analysts forecast AVXL's earnings for 2026 to be -$31,201,757, with the lowest AVXL earnings forecast at -$29,978,159, and the highest AVXL earnings forecast at -$32,119,456. On average, 3 Wall Street analysts forecast AVXL's earnings for 2027 to be -$52,002,928, with the lowest AVXL earnings forecast at -$49,963,598, and the highest AVXL earnings forecast at -$53,532,426.
In 2028, AVXL is forecast to generate $214,630,268 in earnings, with the lowest earnings forecast at $206,213,395 and the highest earnings forecast at $220,942,923.